Molnupiravir, a drug developed by Merck, will probably be authorized by the FDA in the coming weeks. This paper discusses the development of a shortened synthetic route to produce the medicine.
Finding the target of drug candidates is often challenging. A new technique called µMap ID may speed up this process.
Although many repurposed drugs entered trials against COVID-19 in the past year and a half, only one drug has been proven to be efficacious. What happened?
Two proteins in the surface of GAS bacterium are able to bind to damaged collagen. Thus facilitating the infection of this pathogen in wounds.
Mycobacteria, the pathogen that causes tuberculosis, is able to avoid being attacked by the immune system. A unique lipid in its outer membrane plays a major role.
Recently discovered tick enzyme can attack human skin bacteria, protecting ticks while they feed from human blood.